A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis

British Journal of Cancer

Volumn 112, Issue 1, 2015, Pages 69-76

  Biselli, M ^a   Conti, F ^a   Gramenzi, A ^a   Frigerio, M ^a   Cucchetti, A ^a   Fatti, G ^a   D'Angelo, M ^a   Dall'Agata, M ^a   Giannini, E G ^b   Farinati, F ^c   Ciccarese, F ^d   Andreone, P ^a   Bernardi, M ^a   Trevisani, F ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d Divisione di Chirurgia   (Italy)

Author keywords

cirrhosis; hepatocellular carcinoma; surveillance; fetoprotein

Indexed keywords

ALPHA FETOPROTEIN; AFP PROTEIN, HUMAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CONTROL; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER SCREENING; CASE CONTROL STUDY; CHILD PUGH SCORE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ECHOGRAPHY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PREVALENCE; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; CARCINOMA, HEPATOCELLULAR; CHEMISTRY; LIVER NEOPLASMS; MIDDLE AGED; PROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 84920665110     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.536     Document Type: Article

References (26)

1. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J (2001) Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL Conference. J Hepatol 35: 421-430.
2. Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022.
3. Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siauw CP, Chao PL, Tung JN (2007) Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. J Gastroenterol Hepatol 22: 669-675.
4. Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D, Duca P (2006) Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 101: 513-523.
5. Cucchetti A, Cescon M, Erroi V, Pinna AD (2013) Cost-effectiveness of liver cancer screening. Best Pract Res Clin Gastroenterol 27: 961-972.
6. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok AS, Lee WM, Morgan TR, Ghany MG, Gretch DR (2005) Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 43: 434-441.
7. European Association for the Study of the Liver; European Organization for Research and Treatment of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56: 908-943.
8. Giannini EG, Cucchetti A, Erroi V, Garuti F, Odaldi F, Trevisani F (2013) Surveillance for early diagnosis of hepatocellular carcinoma: How best to do it? World J Gastroenterol 19: 8808-8821.
9. Gupta S, Bent S, Kohlwes J (2003) Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 139: 46-50.
10. Hanley JA, McNeil BJ (1983) A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148: 839-843.
11. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150.
12. Kobayashi K, Sugimoto T, Makino H, Kumagai M, Unoura M, Tanaka N, Kato Y, Hattori N (1985) Screening methods for early detection of hepatocellular carcinoma. Hepatology 5: 1100-1105.
13. Lee JM, Trevisani F, Vilgrain V, Wald C (2011) Imaging diagnosis and staging of hepatocellular carcinoma. Liver Transpl 17: S34-S43.
14. Lee E, Edward S, Singal AG, Lavieri MS, Volk M (2013) Improving screening for hepatocellular carcinoma by incorporating data on levels of a-fetoprotein, over time. Clin Gastroenterol Hepatol 11: 437-440.
15. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL, Dienstag JL (2010) Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 138: 493-502.
16. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, Dalhgren J, Chia D, Lok AS, Wagner PD, Srivastava S, Schwartz M (2009) Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 137: 110-118.
17. Nguyen MH, Garcia RT, Simpson PW, Wright TL, Keeffe EB (2002) Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology 36: 410-417.
18. Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, Singh H, Chow WC, Ooi LL, Chow P, Khin MW, Koo WH (2009) Asian Oncology Summit. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 10: 1111-1118.
19. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60: 646-649.
20. Richardson P, Duan Z, Kramer J, Davila JA, Tyson GL, El-Serag HB (2012) Determinants of serum alpha-fetoprotein levels in hepatitis C-infected patients. Clin Gastroenterol Hepatol 10: 428-433.
21. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA (2009) Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 30: 37-47.
22. Stefanini GF, Amorati P, Biselli M, Mucci F, Celi A, Arienti V, Roversi R, Rossi C, Re G, Gasbarrini G (1995) Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience. Cancer 75: 2427-2434.
23. Teefey SA, Hildeboldt CC, Dehdashti F, Siegel BA, Peters MG, Heiken JP, Brown JJ, McFarland EG, Middleton WD, Balfe DM, Ritter JH (2003) Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US and PET. Radiology 226: 533-542.
24. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, Domenicali M, De Notariis S, Roda E, Bernardi M (2001) Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 34: 570-575.
25. Trevisani F, De Notaris S, Rapaccini G, Farinati F, Benvegnù L, Zoli M, Grazi GL, Del PP, Di N, Bernardi M (2002) Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 97: 734-744.
26. Zhang BH, Yang BH, Tang ZY (2004) Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130: 417-422.